| MicroRNA expression patterns in canine mammary cancer show significant differences between metastatic and non-metastatic tumours M Bulkowska, A Rybicka, KM Senses, K Ulewicz, K Witt, J Szymanska, ... BMC cancer 17, 1-17, 2017 | 55 | 2017 |
| Epigenetic mechanisms underlying the dynamic expression of cancer-testis genes, PAGE2,-2B and SPANX-B, during mesenchymal-to-epithelial transition S Yilmaz-Ozcan, A Sade, B Kucukkaraduman, Y Kaygusuz, KM Senses, ... PloS one 9 (9), e107905, 2014 | 39 | 2014 |
| Adjuvant autologous melanoma vaccine for macroscopic stage III disease: survival, biomarkers, and improved response to CTLA‐4 blockade M Lotem, S Merims, S Frank, T Hamburger, A Nissan, L Kadouri, J Cohen, ... Journal of immunology research 2016 (1), 8121985, 2016 | 33 | 2016 |
| Downregulation of DNAJC10 (ERDJ5) is associated with poor survival in breast cancer T Acun, KM Senses Breast Cancer 27 (3), 483-489, 2020 | 12 | 2020 |
| Cancer-testis gene expression is associated with the methylenetetrahydrofolate reductase 677 C>T polymorphism in non-small cell lung carcinoma KM Senses, M Gonen, AR Barutcu, Z Kalaylioglu, M Isbilen, O Konu, ... BMC Medical Genetics 14, 1-6, 2013 | 9 | 2013 |
| Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma KM Senses, M Ghasemi, MW Akbar, M Isbilen, AL Fallacara, ... Medchemcomm 8 (1), 88-95, 2017 | 8 | 2017 |
| Predicting chemotherapy sensitivity profiles for breast cancer cell lines with and without stem cell-like features M Isbilen, K Mert Senses, A Osmay Gure Current Signal Transduction Therapy 8 (3), 268-273, 2013 | 5 | 2013 |
| Predictive gene signature for pyrazolopyrimidine derivative c-Src inhibitor 10a sensitivity in melanoma cells B Kucukkaraduman, C Turk, AL Fallacara, M Isbilen, KM Senses, ... ACS Medicinal Chemistry Letters 11 (5), 928-932, 2020 | 4 | 2020 |
| DNAJC10 (ERDJ5) is a novel biomarker candidate in breast cancer. T Acun, KM Senses Erciyes Medical Journal 41 (S1), 17-19, 2019 | | 2019 |
| Clinical Study Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade M Lotem, S Merims, S Frank, T Hamburger, A Nissan, L Kadouri, J Cohen, ... | | 2016 |
| Predicting effective single molecule inhibitors in distinct subpopulations of melanoma KM Senses, M Ghasemi, M Isbilen, IA Deniz, FN Arslan, A Lucia, ... | | |
Ali Osmay GureSkopos Global Ltd. Istanbul, Turkey在 bilkent.edu.tr 的电子邮件经过验证
